secwatch.observer — SEC 8-K summary
======================================

Issuer:     BOSTON SCIENTIFIC CORP (BSX)
CIK:        0000885725
Form:       8-K
Filed at:   2026-03-30T23:59:59+00:00
Accession:  0000885725-26-000029
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boston Scientific reports positive HI-PEITHO and CHAMPION-AF trial results
--------------------------------------------------------------------------

- HI-PEITHO: EKOS plus anticoagulation reduced primary endpoint events by 61% vs anticoagulation alone (4.0% vs 10.3%, P=0.005).
- HI-PEITHO: No episodes of intracranial bleeding through 30 days; results published in NEJM.
- CHAMPION-AF: WATCHMAN FLX showed 45% relative reduction in non-procedural major bleeding vs NOACs (10.9% vs 19.0%, P<0.001).
- CHAMPION-AF: Primary efficacy endpoint met with non-inferiority to NOACs for stroke, CV death, or systemic embolism (5.7% vs 4.8%).
- Both trials presented at ACC.26 and simultaneously published in The New England Journal of Medicine; data support expanded indications.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000029/0000885725-26-000029-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/885725/000088572526000029/bsx-20260328.htm
  HTML page:      https://secwatch.observer/filing/0000885725-26-000029

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer